Bayer’s Menopause Drug Elinzanetant Achieves Successful Long-Term Results in Phase III Trial, Rivalling Astellas’ Veozah

1. Bayer reports positive results from their third Phase 3 trial for elinzanetant, a drug aimed at reducing hot flashes and improving sleep in menopausal women with moderate-to-severe symptoms.
2. Elinzanetant demonstrated a statistically significant reduction in the frequency of moderate to severe hot flashes at Week 12, with an overall consistent safety profile over 52 weeks.
3. The drug has now achieved success across all three Phase 3 clinical trials, addressing the long-term efficacy question posed by OASIS 3.
4. Elinzanetant targets neurokinin-1 (NK-1) and 3 receptors, which may have additional benefits for insomnia and mood disorders unrelated to menopause.
5. Bayer plans to share detailed data from these studies at upcoming scientific congresses and intends to seek regulatory approval for elinzanetant as a treatment for moderate to severe vasomotor symptoms associated with menopause.
6. Astellas currently markets Veozah, a competitor drug that was approved last year, but it faces commercial challenges due to lower-than-expected demand and issues with insurer reimbursement.
7. Both molecules are designed to bring relief for hot flashes without using hormones, but elinzanetant's dual-target approach could potentially differentiate its effectiveness.